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INTRODUCTION
Colorectal cancer currently ranks the second most common 
cancer in males and the third most common in females in Ko-
rea. Among colorectal cancers, nearly 40–50% are rectal can-
cers.1 The goals of surgical treatment for rectal cancer are com-
plete removal of the rectal cancer and preservation of sexual 
and voiding functions. Preoperative chemoradiation therapy 
(CRT) has been gaining popularly. According to NCCN guide-
lines, long-course 5-fluorouracil-based concurrent CRT is rec-
ommended in rectal patients with cT3,4 N0/+ disease. Howev-
er, this recommendation does not include tumors with a th-
reatening circumferential resection margin.
The standard long-course CRT is more common in North 
America and Korea; short-course radiotherapy is more com-
mon in European countries. Preoperative CRT has been dem-
onstrated to be effective in local control of tumors and for anal 
sphincter preservation in large, prospective, randomized clin-
ical trials.2,3
A prospective German rectal cancer study compared pre-
operative and postoperative CRT among patients with locally 
advanced rectal cancer (LARC) and found a dramatic decrease 
in rate of local recurrence, although no survival benefits, in a 
preoperative CRT group. A Dutch rectal cancer study compared 
preoperative short-course radiotherapy followed by surgery 
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with surgery alone and revealed that preoperative short-course 
radiotherapy decreased the rate of local recurrence; however, 
it had no survival benefits.2 In contrast, an NSABP R-03 pro-
spective randomized trial compared preoperative versus post-
operative CRT for the treatment of LARC and showed survival 
benefits in the preoperative CRT arm in terms of five-year dis-
ease-free survival and overall survival. Interestingly, the five-
year locoregional recurrence rate was the same for each treat-
ment arm.4 It is apparent that preoperative CRT has a definite 
role in disease control and contributes to improved survival in 
patients with LARC. 
Tumor response to preoperative CRT is evaluated based on 
tumor (ypT) and nodal (ypN) down staging and tumor regres-
sion grade (TRG), which correlate significantly with local re-
currence and survival outcomes.5,6 After preoperative CRT, a 
wide range of tumor responses has been observed, from com-
plete remission (CR, ypT0N0) to disease progression. If a tu-
mor shows CR after preoperative CRT, we expect an excellent 
prognosis. According to the literature, 10–30% of patients who 
receive preoperative CRT show CR, and 60% showed a reduc-
tion in tumor size and T and N down staging (Fig. 1A),7,8 though 
some patients showed a poor response with little or no tumor 
reduction (Fig. 1B).5,6 Furthermore, even though primary rec-
tal cancer showed a dramatic reduction in tumor size and 
down staging, liver metastasis and systemic lymph node me-
tastasis developed during preoperative CRT (Fig. 2). This dis-
crepancy between tumor responses of the primary tumor and 
disease progression is sometimes observed. 
EVALUATION MODALITIES FOR 
ASSESSMENT AND PREDICTION 
OF TUMOR RESPONSE
Various modalities have been studied and proposed to assess 
and predict responses to CRT. For morphologic assessment of 
tumor response after preoperative CRT, endoscopic findings 
and imaging studies, including magnetic resonance imaging 
(MRI) and positron emission tomography (PET), have been 
used and demonstrate good results. Clinical factors and se-
rum carcinoembryonic antigen (CEA) have also been investi-
gated and shown to hold some predictive value. Notwithstand-
ing, due to the limitations of these modalities, molecular bio-
markers analyzed using immunohistochemistry (IHC) and gene 
expression profiling have been investigated and may play a 
possible role as predictive models for tailored treatment of pa-
tients undergoing preoperative CRT. 
Endoscopic findings
Gross tumor characteristics detected by endoscopy have been 
suggested for assessment of tumor response after preopera-
tive CRT. Habr-Gama, et al.9 attempted to provide a clear defi-
nition of clinical complete response (cCR) after preoperative 
CRT using endoscopic features. They defined the positive and 
negative signs for cCR. Positive signs for cCR frequently in-
cluded whitening of the mucosa, presence of any telangiecta-
sia, subtle loss of pliability of the rectal wall harboring the scar, 
and no gross evidence of residual tumor. In contrast, positive 
Fig. 1. Primary tumor response after preoperative chemoradiation therapy for rectal cancer. (A) Complete pathologic response. (B) Poor response. The 
arrow indicates the residual tumor.
A B
Fig. 2. Systemic progression of disease during preoperative chemoradiation therapy. The arrow indicates the liver metastasis (A) and the paraaortic 
lymph node metastasis (B).
A B
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signs of residual disease included residual deep ulceration, 
superficial ulcer irregularity, palpable nodule, and significant 
stenosis (Fig. 3). It was suggested that regularly scheduled re-
assessments might provide a safe alternative to patients with 
endoscopic findings of cCR. 
Smith, et al.10 conducted a retrospective study of nonopera-
tive management (NOM) of rectal cancer with cCR after neo-
adjuvant CRT. Thirty-two patients were treated with NOM af-
ter cCR. Fifty-seven patients (22%) demonstrated pathologic 
complete response (pCR) and formed the control group. The 
NOM group showed six local recurrence cases and concur-
rent distant recurrences were observed in three cases. Salvage 
rectal resection controlled all six local failures with no further 
local recurrence. The pCR group after rectal resection demon-
strated no local failures. The two-year distant disease-free sur-
vival (88% vs. 98%, p=0.27) and overall survival (96% vs. 100%, 
p=0.56) were similar between the NOM and pCR after rectal 
resection groups. Local control without rectal resection was 
successful in 81% of patients in NOM group. When combined 
with salvage surgery, NOM achieved similar local and distant 
disease control compared with pCR after rectal resection.
We performed a prospective study to evaluate the predic-
tion of a pCR based on endoscopic findings in 71 rectal cancer 
patients after preoperative CRT and following surgical resec-
tion (unpublished data). We ventured a hypothesis that no vi-
sualization of tumor, white scar, or red scar would be associat-
ed with “cCR” and ulcerations and remaining masses of any 
size would be associated with “non-cCR.” Twenty-four (33.8%) 
patients showed pCR. Of the 23 patients that demonstrated 
endoscopic cCR, 19 (82.6%) showed pCR. Of the 48 patients 
that demonstrated endoscopic non-cCR, 43 (89.6%) showed 
non-pCR. For assessment of pCRs, endoscopic findings ex-
hibited 81.8% sensitivity and 91.8% specificity. Endoscopic 
findings were significantly correlated with tumor response af-
ter preoperative CRT for rectal cancer. Notably, endoscopic 
cCR showed a high specificity for assessment of pCRs and 
might be valuable as a predictive tool.
Magnetic resonance imaging (MRI)
An MRI can be used to indicate tumor response 4–8 weeks af-
ter completion of preoperative CRT. MRI has the advantage of 
detailed and wide view to investigate the pelvic anatomy in 
advanced rectal cancer patients rather than endorectal ultra-
sonography.11 Threfore, surgeon can get the more information 
Fig. 3. Various endoscopic findings of primary tumors after preoperative chemoradiation therapy. (A) Whitening of the mucosa. (B) Association of telangi-
ectasia. (C) Deep ulceration. (D) Palpable nodule.
A
C
B
D
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from MRI after preoperative CRT to decide the resection plan 
and extent of surgery. Although MRI demonstrate the high ac-
curacy for local staging of rectal cancer without preoperative 
treatment, the lower accuracy was observed in assessing the 
ypT stage after preoperative CRT. From the report of pooled 
data analysis for more than 1500 patients, the disappointing 
results were observed with a low sensitivity of 50% for assess-
ment of ypT stage, but relatively high specificity of 91%.12 Fur-
thermore, the sensitivity for assessment of ypT0 was only 19%. 
On the other hand, a higher specificity of 94% was observed.11 
The high specificity means that surgeon can select patients 
who need the radical surgery for remnant tumor even after 
preoperative CRT. In contrast, patients who have good re-
sponse can be underestimated and receive more extended sur-
gery without a chance of organ preservation. The findings above 
suggest that MRI has some limitations to distinguish remnant 
tumor cells and fibrotic change after preoperative CRT. Small 
viable tumor cells can be missed or fibrotic tissue can be over-
estimated to remnant cancer tissue (Fig. 4). 
Some reports demonstrated the good performance of MRI 
volumetric measurements of tumor to assess the tumor shrink-
age after preoperative CRT and accuracies was up to 87%.13,14 
Dresen, et al.13 found that the combination of an initial tumor 
volume ≤50 cm3 and a ≥75% volume reduction rate on post-
CRT MRI predict ypT0–2 with accuracy of 87%. Curvo-Semedo, 
et al.15 and Ha, et al.16 found areas under the receiver operation 
characteristic (ROC) curve (AUCs) of 0.70–0.84 for the assess-
ment of pathological complete response with MRI volumetric 
measurements. 
In our previous work, we evaluated the impact of tumor vol-
ume changes assessed by three-dimensional (3D) volumetry 
on tumor response. Eighty-four patients who underwent pre-
operative CRT followed by radical surgery were prospectively 
enrolled in the study. The post-treatment tumor volume and 
tumor volume reduction ratios (% decrease ratio), as shown 
by 3D MR volumetry, were compared with the histopatholog-
ic response. In a multivariate analysis, the tumor volume re-
duction ratio was not significantly associated with T or N down 
staging. However, the volume reduction ratio (>75%, p=0.01) 
was significantly associated with an increased pCR rate.17
To evaluate a good tumor response after preoperative CRT 
in rectal cancer, some MRI features including invasion depth 
Fig. 4. Various findings according to MRI after preoperative chemoradiation therapy for rectal cancer. Good response: (A) MRI before preoperative CRT; 
(B) MRI after preoperative CRT. Poor response: (C) MRI before preoperative CRT; (D) MRI after preoperative CRT. CRT, chemoradiation therapy.
C
A B
D
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of tumor, tumor volume, and tumor characteristics were us-
ed.13,18,19 No lymph node metastasis, absence of extramural ve-
nous invasion, and no evidence of mucinous component, have 
also been reported to correlate with improved response.18,19 
Furthermore, MRI features could be a predictive factor of dis-
tant metastasis in LARC. Sohn, et al.20 showed that three fac-
tors, positive extramural vascular invasion (EMVI), high T stage, 
and positive regional lymph node metastasis, were significant-
ly associated with synchronous distant metastasis within six 
months. On their own, these features are insufficient to predict 
treatment response and plan a tailored treatment strategy in-
dividually. However, MRI is definitely meaningful modality for 
prediction of preoperative CRT as a part of combined model. 
Advances in functional magnetic resonance technology 
combine morphological information with information on the 
biological microenvironment of the tumor. Functional MRI 
could provide a more comprehensive picture of tumor het-
erogeneity and its changes in response to preoperative CRT. 
Some of these functional technologies have been already used 
in clinical practice, including perfusion imaging [dynamic 
contrast-enhanced MRI (DCE-MRI)] and diffusion-weighted 
MRI (DW-MRI). Other technologies, such as metabolic imag-
ing with MRI (1H, 13C magnetic resonance spectroscopy), are 
still in the experimental phase.21,22
Perfusion MRI and DCE-MRI demonstrate the angiogenic 
activity of tumor vasculature by measuring the pharmacoki-
netics of an intravenously administered contrast agent. These 
perfusion characteristics can be evaluated in a qualitative, qu-
antitative, or semi-quantitative manner.23 The wash-in rate 
Ktrans is volume transfer content between plasma and extra-
Fig. 5. Perfusion MRI imaging. (A) Good response. (B) Poor response.
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vascular space, and correlated with the permeability of tumor 
vasculature. Ktrans is the most popular perfusion parameter 
in quantitative analysis.24 Gollub, et al.25 evaluated the value of 
Ktrans before and after preoperative chemotherapy for LARC 
and found a significantly lower post-treatment Ktrans for pCR, 
compared to that of non-pCR (p=0.04). George, et al.26 and Lim, 
et al.27 studied the predictive value of pretreatment Ktrans in 
rectal cancer patients received preoperative CRT and good re-
sponder showed a higher Ktrans than poor responder (Fig. 5). 
Oberholzer, et al.28 also observed same findings that the high-
er pretreatment Ktrans was correlated with tumor down stag-
ing. On the other hand, Devries, et al.29 and Kremser, et al.30 
showed that, Ktrans before preoperative CRT was higher in 
down staging (-) tumors, compared to down staging (+) tumors.
DW-MRI provides qualitative and quantitative information 
about the basic cellular architecture of the tissue based on dif-
ferences in movement (diffusion) of water protons within the 
various tissues. Tissues with high cellular density like malig-
nant tumor show restricted proton movement and an enhanc-
ed signal on DW-MRI images. Numbers of studies have report-
ed the efficacy of DW-MRI to distinguish the fibrosis from re-
mnant tumor tissue after chemoradiaton in rectal cancer. Ac-
cording to a meta-analysis, DW-MRI can improve the diagnos-
tic value for the assessment of pCR after preoperative CRT in 
rectal cancer, with an increase in sensitivity from 19% to 84%. 
Lambregts, et al.31 reported a effectiveness of DW-MRI for iden-
tifying residual tumor and distinguishing non-pCR with a NPV 
of 90%.
The apparent diffusion coefficient (ADC) is the objective 
value of DW-MRI. ADC values increase during and after CRT 
in rectal cancer, which indicate cell death and tumor necrosis. 
The higher ADC is generally shown in good tumor responders, 
and a potential predictive biomarker of chemoradiation.32-35 
Significant differences of mean ADC after preoperative CRT 
have been observed between good versus poor responders; 
however, a substantial variation and conflicting results is also 
found in several studies.33,34,36 
Changes in ADC before and after CRT are also different be-
tween responders and non-responders. The research of Jung, 
et al.34 and of Intven, et al.37 found a significantly greater in-
crease in ADC in responders than in non-responders.35
The value of pretreatment ADC has been studied as a pre-
dictor of response to CRT. Sun, et al.32 found that pretreatment 
mean ADC of patients with good response was lower than 
that of patients with poor response. In contrast, Barbaro, et al.38 
reported a high pretreatment ADC for good responders. Lam-
brecht, et al.35 and Intven, et al.37 found significantly higher pre-
treatment ADC values in patients resulting pCR than non-pCR.
In summary, the basis of potential predictive imaging bio-
marker in rectal cancer after preop CRT is more evident for 
DW-MRI than DCE-MRI; however, for both, results are drawn 
mainly from small, single-center studies. Further investigation 
through prospective large-scale studies and combined man-
ner are needed to find a promising imaging biomarkers of tr-
eatment response in rectal cancer.
Fluorine-18-fluorodeoxyglucose (18F-FDG) positron 
emission tomography (PET)
Fluorine-18-fluorodeoxyglucose (18F-FDG) PET is being in-
creasingly used for staging and evaluating treatment response 
in oncology. Many researchers studied 18F-FDG PET to assess 
and predict responses to CRT in rectal cancer, and various pa-
rameters have been investigated.39-47 Maximum voxel stan-
dardized uptake value (SUVmax) is defined as the ratio of ra-
dioactivity concentration to the injected activity divided by 
body weight. ΔSUV was defined as the SUVmax-pre–SUVmax-
post difference, and the percentage decrease between the SU-
Vmax-pre and the SUVmax-post is presented as the response 
index (RI)=[ΔSUV/pre-SUV]×100. The percentage change in 
total lesion glycolysis (TLG) before and after CRT (ΔTLG%) is 
another semi-quantitative parameter. One qualitative param-
eter related to 18F-FDG PET, visual response (VR), was assess-
ed for predicting pathologic response to preoperative CRT 
(Table 1).39-47 
The diagnostic performances of the three parameters (RI, 
SUVmax-post, and VR) related to 18F-FDG PET were similar in 
predicting pathological response. The parameter ΔTLG% had 
higher specificity than the other three parameters in predict-
ing pathological response.42-45 
Most studies have used several parameters but find just one 
or two to be correlated with CRT response.40-45,47 In our previ-
ous study,40 a lower SUVmax-post and a higher RI were shown 
in good tumor response (T-down staging and TRGs 1 and 2). 
The SUVmax-post and RI were also significantly associated 
with pathological treatment response, especially in pCR (Fig. 6). 
Maffione, et al.46 used eight parameters to predict TRG, and 
found SUVmax, RI, VR, and ΔTLG% to be significantly correlat-
ed with pathological treatment response, with SUVmax-post 
having the highest sensitivity for predicting TRG.
Janssen, et al.48 studied the optimal time point for repeated 
18F-FDG PET during preoperative CRT and the best factor for 
the prediction of pathological treatment response in patients 
with LARC. Thirty patients were prospectively enrolled and un-
derwent sequential PET-CT imaging at four time points: prior 
to therapy, at days 8 and 15 during CRT, and shortly before 
surgery. Based on TRG evaluations, 13 patients were classified 
as pathological responders (TRG 1–2), while 17 patients were 
classified as pathological non-responders (TRG 3–5). The RI 
for SUVmax on day 15 of CRT was found to be the best predic-
tive factor for pathological response.
At present, many parameters are used to assess response to 
preoperative CRT. Both RI and SUVmax-post showed a similar 
sensitivity and specificity for predicting TRG, and pCR and 
could be suitable indicators of tumor response for preopera-
tive CRT in patients with rectal cancer.40-45,47
Even though several 18F-FDG PET parameters have been 
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used to assess CRT response in LARC, it has clinical limita-
tions. First, the results of the predicting value of 18F-FDG PET 
are so various and not clear. Second, 18F-FDG has weakness in 
assessing lymph node metastasis. Third, 18F-FDG PET has dif-
ficulty distinguishing between residual cancer and physiologic 
uptake by inflammation or fibrotic change after CRT. Fourth, 
the specificity of the predictive value is too low to change or mo-
dify the treatment strategy with confidence.
Currently, 18F-FDG PET is not widely available for use as a 
predictor of tumor response to preoperative CRT. For the opti-
mal prediction of tumor response, it is necessary to coordinate 
decisions with morphological imaging techniques (TRUS, 
MRI) and functional techniques (18F-FDG PET). Therefore, 
multi-institutional prospective studies are needed to determine 
the feasibility of 18F-FDG PET for the tailored treatment of pa-
tients who receive preoperative CRT.
Serum carcinoembryonic antigen (CEA)
CEA is the most widely used tumor marker in patients with rec-
tal cancer. Compared with other potential predictive markers, 
measurement of serum CEA level is inexpensive, standard-
ized, widely used, and easily performed. In recent years, many 
studies have focused on the predictive value of CEA level in pa-
tients with rectal cancer receiving preoperative CRT (Table 2). 
Most studies have shown low pre-CRT CEA (CEA-pre) levels 
with different cut-off values to be associated with good tumor 
response or pCR, although the results of the CEA-pre predic-
tive values are not consistent.49-54 Our previous study showed 
that pretreatment CEA (≤3 ng/mL) is significantly associated 
with an increased rate of pCR.17 
On the other hand, some studies have shown the correla-
tion of post-CRT CEA (CEA-post) level with CR. Perez, et al.,49 
Yang, et al.51 did not find a correlation between initial CEA-pre 
level and pCR, but reported that a CEA-post level <5 ng/mL 
was associated with increased rates of clinical CR and pCR. 
CEA-post with a cut-off value of 2.7 ng/mL was also shown to 
be an independent predictor of good tumor regression. In a 
recent study, CEA-post <2.61 ng/mL also showed a strong 
predictive value for pCR, with a sensitivity of 76.0% and speci-
ficity of 58.4% in patients with low CEA-pre level or high CEA-
pre level but normalized CEA-post level.53 
In the first retrospective study of CEA-change as a predictor, 
a lower CEA-pre level or higher CEA-pre level with a CEA re-
duction ratio ≥70% was found to have a better five-year DFS.50 
However, it was unknown whether or not this ratio was related 
to pCR. To ensure that the CEA ratio (defined as CEA-post di-
vided by CEA-pre) can be used as a predictor for pCR, Yang, et 
al.51 noted that when CEA-pre level ≥6 ng/mL, the CEA ratio 
was a significant predictor of pCR, and the optimal cutoff val-
ue of CEA ratio was 0.22 with a sensitivity of 87.5% and speci-
ficity of 76.7%. 
Compared with other potential prognostic and predictive 
Table 1. Recent Studies of SUV as a Predictor of Responses to CRT among Patients with LARC
Ref. No. Parameter Sensitivity (%) Specificity (%) Cut-off value Conclusion
Amthauer, et al.41 22 ΔSUVmax 93 100 36% ΔSUVmax was significantly greater in responders than 
  in non-responders. 
Hur, et al.40 37 SUVmax-post 84.6 79.2 3.35 SUV-post and RR were significantly associated with 
  pathological treatment response, especially in pCR. 
Capirci, et al.47 87 RI 84.5 80 65% RI was the best predictor of CRT response. 
Martoni, et al.43 80 SUVmax-post
RI 
88
94
34
31
5.0
66%
SUVmax-post supplied limited predictive information.
Maffione, et al.46 69 SUVmax-post 
MTVpost 
TLGpost 
RI 
ΔMTV% 
ΔTLG 
VRA 
85.4
86.7
65.3
85.7
83.7
69.4
69
80
80
75
70
80
80
55
5.1 
2.1 cm3 
23.4 cm3 
61.8% 
81.4% 
94.2%
SUVmax, MTV and TLG after CRT, RI, ΔMTV%, and 
  ΔTLG% parameters were significantly correlated with 
  pathological treatment response. SUVmax-post 
  demonstrated the highest AUC, sensitivity, 
  and specificity. 
SUV, standardized uptake value; CRT, chemoradiotherapy; LARC, locally advanced rectal cancer; pCR, pathological complete response; SUVmean, mean SUV; 
SUVmax, maximum SUV; SUVmean-post, mean SUV of post CRT; SUVmax-post, maximum SUV of post CRT; ΔSUVmax, SUVmax-pre-SUVmax-post; RI, response 
index (SUVpre-SUVpost)/SUVpre; MTV, metabolic tumor volume; ΔMTV%, (MTVpre-MTVpost)/MTVpre; TLG, total lesion glycolysis (SUVmean×MTV); VRA, vi-
sual response assessment.
Fig. 6. 18F-FDG PET before and after preoperative chemoradiation therapy 
for rectal cancer. (A) Before and (B) after in a pathologic complete re-
sponse case. (C) Before and (D) after in a poor response case. 18F-FDG 
PET, fluorine-18-fluorodeoxyglucose/positron emission tomography.
A B C D
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markers, measurement of serum CEA level is inexpensive, 
widely used, and easily performed; however, different studies 
have used different cut-off values, and most studies did not 
provide the sensitivity or specificity of CEA-post as a predictor 
of CRT response.
Molecular biomarkers
Many molecular markers have been assessed for evaluation 
and prediction of tumor response to preoperative CRT in pa-
tients with rectal cancer according to IHC or direct gene sequ-
encing analysis. More than 40 different biomarkers have been 
explored in the literature, with conflicting results in predicting 
the outcomes of CRT (Table 3). Some of the more promising 
markers are discussed below.
One of the most extensively studied markers is the tumor 
suppressor p53. It plays a vital role in the regulation of the cell 
cycle and is important for genetic stability, cell proliferation, 
apoptosis, and inhibition of angiogenesis. Previous studies 
have shown that nuclear expression of p53 in rectal cancers is 
predictive of treatment failure and that detection of nuclear p53 
using IHC is correlated with resistance to pre-operative CRT.55,56 
Of 21 studies examined, 17 found no correlation between p53 
expression and any survival or outcome measure. Chen, et 
al.57 (n=130) and Bertolini, et al.58 (n=91) published studies of 
large sample sizes and revealed no correlation between mu-
tant p53 expression and treatment outcomes. However, other 
studies did find a correlation between p53 and treatment out-
come. Lin, et al.59 (n=70) determined that pre-treatment tumor 
biopsies negative for p53 are predictive of complete tumor re-
gression or only tumor in situ in surgical specimens (p=0.006). 
Spitz, et al.60 (n=42) found a relationship between samples lack-
ing p53 staining and improved histopathologic response to 
preoperative CRT (p=0.02) and a direct relationship between 
p53 positive-staining samples and residual disease detected 
within lymph nodes (p=0.02). In contrast, Esposito, et al.61 (n= 
38) found that pre-treatment biopsies (PTB) showing strong 
expression of p53 were associated with better responses to pre-
operative CRT. Our results are consistent with studies showing 
an association between strong p53 positivity and tumor resis-
tance to CRT, and our multivariate analysis identified p53 as 
an independent predictor of pCR.62
Wild-type p53 protein induces the expression of p21, a prod-
uct of the WAF1/CIP1 gene. Charara, et al.63 (n=57) and Rau, et 
al.64 (n=66) both found that p21 expression is associated with 
a good/complete response. On the other hand, Reerink, et al.65 
(n=34) found higher p21 expression to be associated with 
poorer survival, while Bertolini, et al.58 (n=91) found no corre-
lation between p21 expression and pathological response, th-
ough they did find a reduction in disease-free survival with 
high p21 expression. In our cohort, strong expression of p21 
was observed significantly more often among good respond-
ers and was significantly associated with pCR.62 
Ki-67 has been used to assess cell proliferation and activity 
and can be detected in all active stages of the cell cycle; two 
previous studies showed an association between Ki-67 and 
treatment response. Our earlier study66 (n=23) showed that 
good treatment responders have a higher Ki-67 index (num-
ber of Ki-67 staining tumor cells per 1000 cells), whereas Ja-
kob, et al.67 (n=22) showed the opposite. In our cohort, Ki-67 
index was significantly higher in good responders, as deter-
mined based on ypTNM, T-down staging, N-down staging, 
TRG, and pCR. Furthermore, Ki-67 was an independent predic-
tor of pCR. Other studies have found no association between 
Ki-67 expression in PTB and any measure of outcomes.62,68 
The bax and bcl-2 proteins belong to the bcl-2 subset of on-
cogenes involved in the apoptosis pathway. One of the three 
studies examining bax expression and outcome in preopera-
tive CRT treatment have revealed a significant correlation.69 
Chang, et al.70 (n=130) found that the complete-response group 
had 54% bax-positive pretreatment tumor biopsies, compared 
with 29% bax-positive biopsies in the partial-response group 
(p=0.017). More studies evaluating bax as a predictive bio-
marker are needed to remedy the limited data available. Of 12 
total studies that evaluated bcl-2’s potential as a predictive 
Table 2. Recent Studies of CEA as a Predictor of Responses to CRT among Patients with LARC
Ref. No. Parameter Cut-off value p value Conclusion
Park, et al.52 352 CEA-pre 3 ng/mL <0.001 CEA-pre level is of clinical value as a predictor of response to pre-CRT. 
CEA-pre 3.4 ng/mL 0.008 Low CEA-pre was significantly associated with pCR. 
Lee, et al.53 345 CEA-pre 5 ng/mL 0.002 CEA-pre was significant for prediction of pCR. 
Perez, et al.49 170 CEA-post
CEA-pre
CEA-reduction
5 ng/mL 
5 ng/mL 
0.009 (clinical CR) 
0.05 (pCR) 
Low CEA-pre level was associated with an increased rate of cCR but not 
  with pCR. 
There was no correlation between reduction in CEA and CR.
Jang, et al.54 109 CEA-post 2.7 ng/mL 0.015 (clinical CR) 
0.06 (pCR) 
CEA-post was an independent predictor of good tumor regression. 
Yang, et al.51 138 CEA-post
CEA-ratio
2.61 ng/mL 
0.22 ng/mL 
0.001 CEA-post <2.61 ng/mL predicted pCR (sensitivity 76.0%, specificity 58.4%), 
  CEA ratio predicted pCR (sensitivity 87.5%, specificity 76.7%) for those 
  with CEA-pre ≥6 ng/mL.
CEA, carcinoembryonic antigen; CRT, chemoradiotherapy; LARC, locally advanced rectal cancer; pCR, pathological complete response; CEA-pre, pretreatment 
CEA (CEA-pre) level; CEA-post, post-CRT CEA level; CEA ratio, CEA-post divided by CEA-pre; CEA-reduction, CEA-pre-CEA-post.
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biomarker of treatment response, only one revealed a correla-
tion. Kudrimoti, et al.71 (n=17) found that 60% of the complete 
responders were bcl-2 positive on pretreatment biopsy stain-
ing, compared with 16% bcl-2 positive in the partial respond-
ers group (p=0.04). Survivin is another antiapoptotic molecule 
that inhibits members of the caspase family of enzymes. Sarela, 
et al.72 (n=49) showed a correlation between survivin expres-
sion and decreased survival. 
Angiogenesis is essential for tumor growth and survival. 
Therefore, vascular endothelial growth factor (VEGF) is a sub-
ject of investigation in cancer biology. Tumor hypoxia can in-
duce resistance to radiation and chemotherapy by depriving 
cells of oxygen essential for the cytotoxic activities of these 
agents. Only one marker for hypoxia, VEGF, has been assessed 
as a response predictor in rectal cancer.73 Qui, et al.74 examined 
VEGF expression in PTB from 72 patients undergoing long-
course preoperative radiotherapy; they found that the histologi-
cal response was unrelated to pre-treatment VEGF status. In 
contrast, we observed that VEGF expression levels were pre-
dictive of pCR; that is, tumors strongly expressing VEGF on 
tissue microarray (TMA) responded significantly better to 
CRT than did those with weak expression. 
COX 2 is an important mediator of tumor invasiveness and 
metastasis. Smith, et al.75 assessed endogenous COX 2 expres-
sion in PTB of 49 patients undergoing preoperative CRT for 
rectal cancer. Patients with COX 2 overexpression in PTB were 
more likely to demonstrate poor response to RCT (TRG 3 and 4) 
than were those with normal COX 2 expression (p=0.026). Our 
study also demonstrated that patients with COX 2 overexpres-
sion were more likely to show a poor TRG and were less likely 
to achieve histopathologic nodal down staging (p=0.03) than 
those with normal COX 2 expression.76
Epidermal growth factor receptor (EGFR) is expressed in 50 
to 70% of cancers, and therapies targeting this and related path-
ways are increasingly being developed for translational trials. 
Giralt, et al.77 (n=87) found that a significantly higher number 
of EGFR-negative patients achieved pCR, compared with EG-
FR-positive patients. Using multivariate analysis, Kim, et al.78 
(n=183) found that low EGFR expression significantly predicts 
increased tumor down staging with therapy. Spindler, et al.79 
(n=60) found that tumors involving replacement of G with a T 
nucleotide at position 216 of the EGFR promoter (GT or TT ge-
notypes) demonstrated improved response, compared with 
tumors with a GG genotype.
Thymidylate synthase (TS), located on chromosome 18p11.32, 
is an essential enzyme for cell proliferation and deoxyribonu-
cleic acid (DNA) synthesis. Several studies have evaluated the 
efficacy of TS as a predictor of treatment response after CRT 
in rectal cancer. Okonkwo, et al.80 (n=25) and Saw, et al.69 (n= 
60) determined that PTB negative for TS were predictive of tu-
mor down staging in the CRT group (n=35). In contrast, Negri, 
et al.81 demonstrated that PTB demonstrating high TS staining 
intensity had significantly more complete and partial respond-
ers than those exhibiting low TS staining intensity (88% vs. 
12%) in the CRT group (n=19). We investigated the correlation 
of TS gene expression and polymorphisms with tumor resp-
Table 3. Biomarkers and Analysis Methods for Prediction of Responses to Preoperative CRT among Patients with LARC
Ref. No. Biomarker
Analysis 
method
p value Conclusion
Komuro, et al.55 111 p53 IHC 0.045 There was a significant correlation between the expression pattern of p53 
  and tumor radiosensitivity.
Fu, et al.56 49 p53
p21
IHC 0.01 The majority of p53(-) or p21(+) tumors were radiosensitive.
Huh, et al.84 123 13 markers PCR 0.03 Only CD44 expression was found to be a significant independent predictive 
  factor of tumor regression grade response.
Rau, et al.64 66 p53, p21, Ki67 PCR Lower p21 expression in pre-treatment biopsies was correlated with poor 
  response.
Kim, et al.78 183 EGFR IHC 0.012 The significant predictive factor for increased tumor down staging was a low 
  level of EGFR expression.
Zlobec, et al.73 104 EGFR
VEGF
IHC 0.01
0.009
Loss of VEGF and positive EGFR are independent predictors of pCR.
Spindler, et al.79 77 EGFR IHC
SNP
>0.05
0.023
EGFR Sp1-216G/T polymorphism is a potential marker of response to CRT.
Sprenger, et al.83 126 CD133 IHC <0.01 Increased fraction of CD133-expressing cells after preoperative CRT was 
  associated with less histopathologic tumor regression.
Havelund, et al.91 50 HIF-1α IHC There were no significant differences between the HIF-1α-positive group and 
  HIF-1α-negative group with regard to pathological grading and pCR.
CRT, chemoradiotherapy; LARC, locally advanced rectal cancer; pCR, pathological complete response; GE, gene expression; IHC, immunohistochemistry; PCR, 
polymerase chain reaction; TRG, tumor regression grade; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; SNP, single-nucleo-
tide polymorphisms; HIF-1α, hypoxia-inducible factor 1α; GLUT-1, glucose transporter-1.
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onse to preoperative CRT in 44 patients with LARC. Patients 
exhibited 2R/3R and 3R/3R tandem repeat polymorphisms in 
the TS gene. In regard to TS expression in these genotypes, 
2R/3RC and 3RC/3RC were defined as the low expression 
group and 2R/3RG, 3RC/3RG, and 3RG/3RG as the high ex-
pression group. Patients in the low expression group with a 
G>C single-nucleotide polymorphism (SNP) (2R/3RC, 3RC/ 
3RC) exhibited a significantly greater tumor down staging rate, 
compared with patients in the high expression group without 
the SNP (2R/3RG, 3RC/3RG, 3RG/3RG) (p=0.001). The nodal 
down staging rate was also significantly greater in this low ex-
pression group, compared with that of the high expression group.82
Cancer stem cell markers
CD133, CD44, and CD24 have been widely known as colorec-
tal cancer stem cell markers. Cancer stem cell has the charac-
teristics of resistance to chemotherapy and radiotherapy. Th-
erefore, there have been some efforts to investigate the cor-
relation of cancer stem cell markers with the treatment response 
to CRT. CD133 expression means the existence of cancer stem 
cell and high level is correlated with resistance to CRT in LARC.83 
The level of CD24 was also found to be significantly associated 
with CRT response in some reports. Huh, et al.84 revealed that, 
among 13 molecular markers, only elevated CD44 mRNA lev-
el in PTB was predictive of poor tumor regression, and CD133 
level had no significant correlation with CRT response. Until 
now, there is no confirmative result that cancer stem cell mark-
er is predictive of CRT response and useful in clinical field. 
More investigation is needed to develop predictive model us-
ing cancer stem cell markers. 
Gene expression profiling
To overcome the limitation of single specific markers for pre-
dictability, DNA microarray-based gene expression profiling 
technology have been used to analyze a large number of genes 
simultaneously and to search systematically for molecular 
markers to predict CRT responses and outcomes (Table 4).85,86 
Ghadimi, et al.87 used two different microarray platforms to 
analyze PTB, and identified 54 genes that were significantly 
differentially expressed between responders and non-respond-
ers based on T down staging. The genes were able to correctly 
predict tumor behavior in 83% of patients. 
Watanabe, et al.88 studied gene expression profiles, and iden-
tified 33 novel discriminating genes whose expression dif-
fered significantly between responders and non-responders 
among 52 rectal cancer patients who underwent preoperative 
CRT. Using that gene set, they established a new model to pre-
dict responses to CRT in rectal cancer with an accuracy of 82.4%. 
The list of discriminating genes included those related to gr-
owth factors, apoptosis, cell proliferation, signal transduction, 
and cell adhesion. Among the 33 discriminating genes, apop-
tosis inducers (lumican, thrombospondin 2, and galectin-1) 
showed higher expression in responders, whereas apoptosis 
inhibitors (cyclophilin 40 and glutathione peroxidase) showed 
higher expression in non-responders. In a subsequent study, 
Watanabe, et al.89 initially identified differently expressed genes 
between responders and non-responders using microarray an-
alysis. Quantitative reverse transcriptase polymerase chain re-
action was performed to validate the microarray expression le-
vels of the discriminating genes, and the 16 genes showed a 
difference in expression between responders and non-respon-
ders after preoperative CRT. They constructed a predictive mo-
del using different sets of these 16 genes, and the highest ac-
curacy rate (89.1%) was obtained using LRRIQ3, FRMD3, 
SAMD5, and TMC7. The predictive accuracy rate of this four-
gene signature in an independent set of 16 patients was 81.3%.
Kim, et al.90 also investigated whether microarray gene ex-
pression analysis predicted complete response to preopera-
tive CRT in patients with rectal cancer. The reported an accu-
racy of greater than 80%. 
Microarray gene profiling seems to be ideal for identifying 
overall molecular markers that predict response to CRT. How-
ever, although each study has shown the promising results with 
predictive genes for CRT response, there are several limitations 
for the use of microarray in clinical practice. Most important 
aspect is the absence of uniformity of reported gene signa-
tures among studies. The reproducibility is essential for use in 
clinical practice and simplicity is also needed. Microarray is 
still insufficient for these practical aspects. The difficulty of 
fresh tissue handling and high cost is also limitation. However, 
Table 4. Recent Studies Using Gene Expression Profiling to Analyze the Genetics of Response to CRT among Patients with LARC
Ref. No. No. of genes Accuracy (%) Conclusion
Ghadimi, et al.87 30 54 82.4 Pretherapeutic gene expression profiling might assist in response prediction to preoperative CRT.
Watanabe, et al.88 52 33 82.4 Gene expression profiling might be useful in predicting response to radiotherapy. 
Kim, et al.90 46 95 84 Microarray gene expression analysis was successfully used to predict CR to preoperative CRT. 
Rimkus, et al.86 43 42 86 Pretherapeutic prediction of response to CRT based on gene expression analysis represents 
  a new valuable and practical tool for therapeutic stratification. 
Nishioka, et al.85 17 17 Gene expression patterns of diagnostic biopsies can predict pathological response to 
  preoperative CRT. 
Supiot, et al.92 6 31 (up)
6 (down)
Micro-arrays can efficiently assess early transcriptomic changes during preoperative 
  radiotherapy for rectal cancer.
CRT, chemoradiotherapy; LARC, locally advanced rectal cancer; CR, complete response.
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considering the promising data and usefulness of gene profil-
ing in breast and lung cancer, gene expression profiling holds 
considerable promise to identify the underlying complex ge-
netics of responses to CRT of rectal cancer if candidate genes 
are carefully validated.
Single-nucleotide polymorphism (SNP) markers
Genome-wide association studies (GWA) are theoretically ca-
pable of identifying predictive markers of CRT response de-
spite of discordance among studies. SNP analysis has been 
used to investigate special gene sites in order to predict resp-
onses to CRT. Furthermore, thousands of SNPs can be identi-
fied by GWA studies. A recent study proposed a novel three-
step approach to the identification of CRT-responsive patients 
based on genome-wide screening, clinical association, and bio-
logical validation of SNP markers.90 Of 691.162 SNPs analyzed 
in the first step using 43 patients, 9 candidate CRT-responsive 
SNPs, including USP20 rs227450, FAM101A rs7955740, ZNF281 
rs424414, OR2T4 rs153870, SLC10A7 rs41398848, CORO2A 
rs1985859, ASZ1 rs7808424 MED4 rs157125, and CDC42BPA 
rs192986 were selected. In the second step, the above nine can-
didate SNPs were genotyped by pyrosequencing using genom-
ic DNA samples from the 43 initial screening patients and 70 
additional patiens for clinical validation and two candidate 
markers were identified. Positive response (TRG 1–3) were ob-
tained more likely in patients carrying the reference allele (C) 
of the SNP CORO2A rs1985859 than in those with the substitu-
tion allele (T).90 Flow cytometry determined the significant as-
sociation between downregulation of CORO2A and reduced 
early apoptosis in colorectal cancer cells. Reduced radiosensi-
tivity was also confirmed by colony-forming assays in the same 
cells in the third step. Otherwise, any genotype or allelotype of 
SNP FAM101A rs7955740 was not associated with radiosensi-
tivity in the clinical association analysis. However, downregu-
lation of FAM101A significantly reduced early apoptosis and 
enhanced colony formation in colorectal cancer cells.
Despite the controversial findings in the study and poor con-
cordance between GWA studies, the finding is novel, and SNPs 
are worth further validation in large cohorts.
FURTHER INVESTIGATIONS AND 
ONGOING STUDIES
Dynamic analysis using sequential evaluation
Dynamic change of molecular marker value was studied to be 
correlated with the response to CRT by sequential biopsies of 
rectal cancer. In one study, biopsies were taken before treat-
ment, after 2, 4, and 6 weeks of CRT and in specimens from the 
operation. Decreasing expressions of hypoxia-inducible fac-
tor 1α, bcl-2, and Ki-67 were observed during CRT, whereas 
glucose transporter-1 overall was unchanged. No significant 
changes of the markers were observed in the interval between 
CRT and surgery. A significant association was observed be-
tween the presence of residual carcinoma after 6 weeks of 
treatment and pathological response to CRT, but no associa-
tion was seen between the fluctuations of any of the markers 
and response to CRT.91 In another study immunohistochemical 
expressions of p21 and apoptosis together with histologic ch-
anges on H&E stained biopsy specimens obtained 7 days after 
starting CRT are strong predictors of response to CRT.72 Mi-
crorray analysis of tumor biopsies after a dose of 7.2 Gy at a me-
dian time of 1 hour following irradiation efficiently assessed 
early transcriptomic changes during preop CRT. Up-regula-
tion of 31 genes and down-regulation of six genes was shown.92 
These studies demonstrate that early or serial evaluation of tr-
eatment response is more accurate and promising rather than 
only before or after CRT. However, biopsy procedure is invasive 
may be harmful to be performed serially. Therefore, non-inva-
sive tools like MRI, PET-CT, and CEA can safely evaluate dy-
namic changes of response in rectal cancer during CRT.93 How-
ever, PET-CT is too expensive to be performed repeatedly, and 
numbers of patients show the normal CEA value before CRT 
and the significant change would not be expected. A study in-
cluding 20 patients who underwent MRI including DWI be-
fore CRT, after 10–15 fractions and 1 to 2 weeks before surgery 
demonstrated that ΔADC-during and after CRT was signifi-
cantly higher in patients with pCR, compared to patients 
without.35 Above findings indicate that sequential evaluation 
modalities may be more useful for prediction and early as-
sessment of treatment response to preop CRT of rectal cancer 
than only one-time evaluation.
Multidirectional evaluation model
Each predictive marker has its own strength and weakness, 
therefore, a combination of two or more predictive models may 
improve its predictability of treatment response after preop 
CRT in rectal cancer. In one prospective study, the combina-
tion of PET-CT and DW-MRI was investigated for the predic-
tion of pCR after CRT in rectal cancer.94 Twenty-two patients 
underwent PET/CT prior to the start of CRT, after 10 to 12 frac-
tions of CRT and five weeks after the end of CRT. A DW-MRI 
was performed before start of CRT. ΔSUVmax during and after 
CRT significantly correlated with pCR after CRT. The initial 
ADC value was also significantly correlated with pCR. ROC 
curve analysis revealed an optimal threshold for ΔSUVmax of 
40% during CRT and 76% after CRT, as well as for ADC value 
of 1.06×103 mm2/s. Combining the provided ΔSUVmax thresh-
olds during and after CRT increased specificity of the predic-
tion (sensitivity 100% and specificity 94%). The combination 
of the thresholds for the initial ADC value and the ΔSUVmax 
during CRT increased specificity of the prediction to a similar 
level (sensitivity of 100% and specifi city of 94%). 
Maas, et al.95 evaluated the feasibility and safety of a wait-
and-see policy among patients without residual tumor on im-
aging or endoscopy (cCR) after preoperative CRT for rectal 
http://dx.doi.org/10.3349/ymj.2015.56.6.14611472
Predictive Biomarkers of Chemoradiation Response
cancer.95 The definition of cCR is 1) substantial downsizing 
with no residual tumor or only residual fibrosis (with low signal 
on high b-value DWI, if available). Residual wall thickening 
due to edema was also an indication for possible cCR, as were 
2) no suspicious lymph nodes on MRI; 3) no residual tumor at 
endoscopy or only a small residual erythematous ulcer or scar; 
4) negative biopsies from the scar, ulcer, or former tumor loca-
tion; and 5) no palpable tumor, when initially palpable with 
digital rectal examination. If patients did not meet all of these 
criteria, they were regarded as non-complete responders. 
Twenty-one patients with cCR were included in the wait-and-
see policy group. Mean follow-up was 25±19 months. One pa-
tient developed a local recurrence and underwent surgery as 
salvage treatment. The other 20 patients are alive without dis-
ease. The control group consisted of 20 patients with pCR after 
surgery with a mean follow-up of 35±23 months. For these 
patients, the cumulative probabilities of two-year disease-free 
survival and overall survival were 93% and 91%, respectively. 
The authors concluded that a wait-and-see policy with strict se-
lection criteria, up-to-date imaging techniques, and follow-up 
is feasible, and results are promising with outcomes at least as 
good as those of patients with pCR after surgery.
The availability of simple, financially feasible, and high-
throughput technology such as TMA-based IHC provides an 
opportunity to develop a panel of biomarkers. To this end, we 
evaluated the differential expressions of molecular markers in 
TMA constructs from stage II/III rectal tumors (n=81) in pa-
tients treated with preoperative CRT.62 Using TMAs and IHC, 
expression levels of 12 candidate biomarkers (p53, p21, bcl-2, 
Bax, EGFR, COX 2, MLH-1, MSH-2, Ku70, VEGF, TS, Ki-67) 
were evaluated in paraffin-embedded tumor samples collected 
before preoperative CRT. The correlations between biomarker 
expression level and pathologic response to preoperative CRT 
were assessed based on histopathological staging (pTNM) 
and TRG. Expression levels of four biomarkers (p53, VEGF, 
p21, Ki-67) were correlated with pCR. Patients showing low ex-
pression of p53 and/or high expressions of VEGF, p21, or Ki-
67 exhibited a significantly greater pCR rate. A scoring system 
devised so that one point was assigned for each biomarker 
whose expression level was correlated with pCR (score range: 
0–4) showed that 1 of 26 patients with scores of 0–1 achieved 
pCR, whereas 26 of 55 patients with scores of 2–4 achieved 
pCR (3.8% vs. 47.3%, p<0.001). For prediction of pCR, the 
scoring system showed 96.3% sensitivity, 46.3% specificity, a 
47.3% positive predictive value, and a 96.2% negative predic-
tive value. 
To date, there have been several attempts to develop models 
or nomograms to predict the outcomes of cancer treatment. 
Keam, et al.96 suggested nomograms predicting clinical out-
comes in breast cancer patients treated with neoadjuvant 
chemotherapy. They developed the nomograms using a logis-
tic regression model for pCR and a Cox proportional hazard 
regression model for relapse-free survival. The nomogram for 
pCR based on initial tumor size, estrogen receptor (ER), hu-
man EGFR 2, and Ki-67 had good discrimination performance. 
A multivariate Cox model identified age less than 35 years, ini-
tial clinical stage, pathologic stage, ER, and Ki-67 as prognostic 
factors, and the nomogram for RFS showed good performance. 
Jwa, et al.97 assessed a nomogram to predict ypN status after 
preoperative CRT in rectal cancer. The nomogram was devel-
oped in a training cohort (n=891) using logistic regression anal-
yses and was validated in a separate cohort (n=258). Patient 
age, preoperative CRT tumor differentiation, cN stage, ypT 
stage, lymphovascular invasion, and perineural invasion were 
reliable predictors of lymph node metastasis after preoperative 
CRT and were used for the construction of the nomogram.
As shown in above published studies, a combination of two 
or more modalities provided complementary information 
about treatment response and yielded higher accuracy and 
specificity than the individual investigations. The combina-
tion of morphological and functional imaging with the numer-
ous potential molecular markers and identified genes will pro-
vide comprehensive information on each individual patient and 
make possible individualized treatment therapy. Combined 
models may be the future trend for predicting treatment re-
sponses.
CLINICAL APPLICATION OF A PREDICTIVE 
MODEL FOR PATIENTS WHO RECEIVED 
PREOPERATIVE CRT
Currently, there is no definite method to predict a tumor re-
sponse to CRT; however, the ability to do so would be of sig-
nificant clinical advantage for several reasons. First, CRT is 
time-consuming, expensive, and increases perioperative mor-
bidity. The ability to predict a response, either before treatment 
or during its early stages, could exclude patients who might 
show poor response and disease progression without benefit. 
Instead, these patients would be candidates for alternative or 
more intensive treatment strategies. Recently, systemic che-
motherapy was offered as initial treatment for patients with 
high-risk LARC in order to target micrometastasis and improve 
tumor response before conventional CRT. Additional chemo-
therapy before CRT and total mesorectal excision resulted in 
substantial tumor regression, rapid symptomatic response, 
and achievement of R0 resection.98-100 Second, prediction of 
complete tumor remission has been regarded as important, 
because it impacts clinical decisions for treatment strategy. In 
cases of cT4 middle or lower rectal cancer that represent inva-
sion of an adjacent pelvic organ, such as the seminal vesicles, 
prostate, vagina, or anal sphincter complex, if CR of rectal can-
cer after preoperative CRT can be predicted, en bloc resection 
of the adjacent pelvic organ or anal sphincter, which results in 
increasing postoperative morbidity and poor quality of life 
with stoma, can be avoided. In addition, local excision or wait-
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and-see treatment strategies can be recommended if the tu-
mor shows an excellent tumor response to preoperative CRT 
for rectal cancer. According to a retrospective analysis of pa-
tients who had received preoperative CRT, ypT0 only has a 5% 
rate of regional lymph node metastasis. However, patients 
who demonstrate adjacent organ involvement and circumfer-
ential margin threatening could be considered for extended 
surgery or additional radiation therapy for curative resection 
(Fig. 7).
The above-mentioned modalities can guide clinicians in 
choosing the best possible treatment for each individual pa-
tients. Nevertheless, there are still controversies regarding out-
comes of each study; in the future, combined models might 
better predict response. The ability to predict pathological tu-
mor response before treatment will significantly impact pa-
tient selection for preoperative CRT and can potentially mod-
ify treatment strategies. 
SUMMARY AND CONCLUSION
The wide range of responses to CRT and its potential toxicity 
generated the investigations to find predictive markers and 
develop an individually treatment model for better outcomes 
in rectal cancer. To use predictive tools for treatment plan and 
clinical practice, the accuracy and effectiveness of markers 
should be proved. However, the clinical application of these 
potential predictive markers is still far and the evidence is in-
sufficient. 
In this review, we provided an overview of different predic-
tive methods. The MRI, 18F-FDG PET, CEA, and molecular 
biomarkers each have potential for predicting responses to 
CRT. However, several methods for prediction of tumor re-
sponses after CRT have shown some limitations in accuracy. 
Therefore, a nomogram for prediction of tumor response with 
high accuracy is needed using multiple evaluation tools, includ-
ing relevant molecular markers.
In the future, when highly accurate predictive tools for good 
tumor response are developed, patients who will benefit from 
preoperative CRT can be identified and treated with individu-
alized methods. Furthermore, if ypT0 can be predicted in lower 
rectal cancer, the extent of surgery can be determined with great 
confidence.
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